SCHEMBL2403293

SCHEMBL2403293

Cc1ccc(S(=O)(=O)NC(Cc2ccccc2)C(=O)N2CCC3(CC2)CC(C(=O)NCc2cccnc2)=NO3)cc1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
KMT2A Q03164 2/20 0.48
KDM4E B2RXH2 1/20 0.48
MEN1 O00255 1/20 0.48
TP53 P04637 1/20 0.48
HPN P05981 3/20 0.44
ST14 Q9Y5Y6 3/20 0.44
HGFAC Q04756 1/20 0.44
PLAU P00749 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
MMP9 P14780 1/20 0.42
CTSL P07711 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
NAMPT P43490 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6409841 0.88 TP53 (0.46) ALDH1A1KMT2AKDM4EMEN1TP53
SCHEMBL6412715 0.86 TP53 (0.56) ALDH1A1KMT2AMEN1TP53HPN
SCHEMBL2581171 0.85 TP53 (0.49) ALDH1A1KMT2AMEN1TP53HPN
SCHEMBL6409811 0.80 TP53 (0.53) ALDH1A1KMT2AMEN1TP53HPN
SCHEMBL15309151 0.78 TP53 (0.45) ALDH1A1KMT2AKDM4EMEN1TP53
SCHEMBL27721615 0.76 ALDH1A1 (0.58) ALDH1A1KMT2AKDM4EMEN1TP53
SCHEMBL6409170 0.75 TP53 (0.47) ALDH1A1KMT2AMEN1TP53HPN
SCHEMBL22500544 0.72 KMT2A (0.70) ALDH1A1KMT2AMEN1TP53HPN
SCHEMBL22500546 0.72 KMT2A (0.70) ALDH1A1KMT2AMEN1TP53HPN
SCHEMBL2400307 0.71 CYP2D6 (0.44) KMT2AKDM4EMEN1CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8048890-B2 Analgesics; neuropathic pain; headaches; muscle relaxants; incontence; tinnitus; diarrhea; antiarrhythmia agents; antiischemic agents; antiinflammatory agents; antiulcer agents; antidepressants; antiepileptic agents GRUENENTHAL GMBH (DE) 2011-11-01 US claimed
US-8048890-B2 Analgesics; neuropathic pain; headaches; muscle relaxants; incontence; tinnitus; diarrhea; antiarrhythmia agents; antiischemic agents; antiinflammatory agents; antiulcer agents; antidepressants; antiepileptic agents GRUENENTHAL GMBH (DE) 2011-11-01 US disclosed
US-20110224172-A1 Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods GRUENENTHAL GMBH (DE) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224172-A1 Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods SULT1E1, DECR1, CYP8B1 ALDH1A1 156/4885KMT2A 3636/4885KDM4E 356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.